Phase II Multicenter Study to Analyze the Predictive Value of Fusion Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Metastatic CRPC no Previously Treated With Chemotherapy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 May 2018
At a glance
- Drugs Enzalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms PREMIERE; PREMIERE-SOGUG
- 31 Aug 2018 Biomarkers information updated
- 26 Jan 2018 Planned End Date changed from 1 Feb 2018 to 1 Jan 2019.
- 26 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.